Atrophy rates in asymptomatic amyloidosis: implications for Alzheimer prevention trials

There is considerable interest in designing therapeutic studies of individuals at risk of Alzheimer disease (AD) to prevent the onset of symptoms. Cortical β-amyloid plaques, the first stage of AD pathology, can be detected in vivo using positron emission tomography (PET), and several studies have s...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one 2013-03, Vol.8 (3), p.e58816-e58816
Hauptverfasser:	Andrews, K Abigail, Modat, Marc, Macdonald, Kate E, Yeatman, Tom, Cardoso, M Jorge, Leung, Kelvin K, Barnes, Josephine, Villemagne, Victor L, Rowe, Christopher C, Fox, Nick C, Ourselin, Sebastien, Schott, Jonathan M
Format:	Artikel
Sprache:	eng
Schlagworte:	Advertising executives Age Aged Aged, 80 and over Alzheimer Disease - diagnosis Alzheimer Disease - prevention & control Alzheimer's disease Amyloidosis Amyloidosis - diagnosis Anti-Alzheimer's disease agents Apolipoprotein E4 Apolipoproteins E - genetics Atrophy Biomarkers Brain Brain - pathology Brain research Clinical trials Cognitive ability Cognitive Dysfunction Correlation analysis Cortex Dementia Disease prevention Emission analysis Feasibility studies Female Geriatrics Health aspects Health risks Hippocampus Humans In vivo methods and tests Load distribution Magnetic Resonance Imaging Male Mathematical analysis Medical imaging Medical research Medicine Neurodegenerative diseases Neuroimaging Neurology NMR Nuclear magnetic resonance Nuclear medicine Older people Organ Size Pathology Plaque, Amyloid Positron emission Positron emission tomography Prevention Senile plaques Studies Tomography Ventricle Ventricles (cerebral) β-Amyloid
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!